Impact of the direct-acting antiviral agents (DAAs) on chronic hepatitis C in Sardinian patients with transfusion-dependent Thalassemia major

Frequency of Thalassemia and Its Association with Hepatitis C Infection in Local Population of Pakistan

“…1,7 Because of precarious CBC values, decreased and continuously fluctuating hemoglobin level and very young age of the patient, it is not appreciable for the accustomed interferon therapy. 19…”

HCV Infection in Thalassemia Syndromes and Hemoglobinopathies: New Perspectives

“…The eradication of the virus determined by the new drugs has also led to a marked improvement in the parameters of martial accumulation, demonstrating a synergic action also between the effect of antiviral therapy and iron chelation (Dharamsi et al, 2017;Nagral et al, 2017;Origa et al, 2017;Premkumar et al, 2017;Mehta et al, 2018;Mangia et al, 2019;Ponti et al, 2019).…”

“…Several trials have been performed on thalassemia patients, while few studies focused on safety, tolerability and efficacy of LDV/SOF treatment for patients with SCD (Moon et al, 2017). The development in recent years of highly effective and increasingly selective DAAs toward different viral genotypes has led to a real revolution in the HCV eradication for patients with thalassemia and hemoglobinopathies, leading to negative viremia and SVR between 90 and 98% (Materazzi et al, 2014b(Materazzi et al, , 2017bNagral et al, 2017;Origa et al, 2017;Mehta et al, 2018;Premkumar and Dhiman, 2018;Mangia et al, 2019;Ponti et al, 2019).…”

Hepatitis C virus therapy in children: No one should be left behind

“…Such populations are represented by patients affected by chronic kidney disease who are on haemodialysis, transfusion‐dependent thalassaemic patients, people living with the human immunodeficiency virus, people who use drugs and children . In these particular groups of patients eradication of HCV infection has a multifold perspective: it allows treating all patients with a given condition, or demographical characteristic, in a reasonably limited period of time, drastically reducing the likelihood of further diffusion of infection within the same communities; it portends an added benefit provided by HCV clearance to the therapeutic management of comorbid conditions; and in the paediatric setting it not only improves the projected health benefit in an otherwise healthy population by eliminating the potential for chronic liver disease progression and the development of associated conditions but also frees young patients from the social and psychological stigmata of a transmissible disease …”